# FCGR2A Gene Polymorphism Association in Children with Multisystem Inflammatory Syndrome

## TL;DR

This study explores how a gene variant in children affects their risk and severity of a rare inflammatory condition called MIS-C.

## Contribution

The study identifies a potential link between FCGR2A gene polymorphism and severe cardiac dysfunction in children with MIS-C.

## Key findings

- No significant association was found between FCGR2A rs1801274 polymorphism and cardiovascular complications in MIS-C patients.
- Children with homozygous FCGR2A rs1801274 polymorphism experienced severe cardiac dysfunction and required additional immunomodulatory treatment.
- Patients with severe MIS-C were older on average and showed significant systolic dysfunction.

## Abstract

Fc gamma receptor IIa (FCGR2A) gene polymorphism is associated with increased susceptibility to autoimmune and infectious diseases. The aim of the present study was to evaluate the association of FCGR2A rs1801274 polymorphism with the development and severity of multisystem inflammatory syndrome in children (MIS-C).

This case-control study was conducted in a single center with MIS-C patients and healthy children. Clinical and cardiac imaging data of the participants was collected. The association between the clinical severity of the disease and FCGR2A rs1801274 polymorphism were investigated.

There was no significant association between FCGR2A rs1801274 polymorphism and cardiovascular complications in MIS-C patients. However, those with homozygous FCGR2A rs1801274 gene polymorphism developed severe cardiac dysfunction and required immunomodulatory agents other than intravenous immunoglobulin. The mean age of the patients with severe MIS-C was significantly higher than those with mild MIS-C, and systolic dysfunction was significant.

Further multicenter studies in different ethnic groups are needed to evaluate the association between differences in the FCGR2A rs1801274 gene and severity of MIS-C and/or other inflammatory diseases.

Mersin University Clinical Trial Registry, Decision number 2022/280 dated April 20, 2022.